• OPEN AN ACCOUNT
Indian Indices
Nifty
25,637.80 88.80
(0.35%)
Sensex
84,058.90 303.03
( 0.36%)
Bank Nifty
57,443.90 237.20
( 0.41%)
Nifty IT
38,822.95 -173.30
( -0.44%)
Global Indices
Nasdaq
43,834.06 426.21
(0.98%)
Dow Jones
6,192.89 30.87
(0.50%)
Hang Seng
40,056.27 471.69
(1.19%)
Nikkei 225
8,798.91 63.31
(0.72%)
Forex
USD-INR
85.73 -0.26
(-0.30%)
EUR-INR
100.32 0.36
(0.36%)
GBP-INR
117.66 0.46
(0.39%)
JPY-INR
0.59 0.00
(0.31%)

EQUITY - MARKET SCREENER

Balurghat Technologies Ltd
Industry :  Miscellaneous
BSE Code
ISIN Demat
Book Value()
520127
INE654B01014
9.6537802
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
BALURTRANS
16.64
35.13
EPS(TTM)
Face Value()
Div & Yield %
1.16
10
0
 

Everest Organics hits the roof after securing KDMF nod for Rabeprazole Sodium API
Feb 18,2025
The Rabeprazole Sodium API is primarily used to treat conditions related to excessive stomach acid production, including gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome, as it acts as a proton pump inhibitor (PPI) by significantly reducing the amount of acid produced in the stomach, essentially helping to heal ulcers and alleviate symptoms like heartburn and acid reflux.

According to the regulatory filing, the company revealed that the approval, granted in February 2025, allows it to export its Rabeprazole Sodium API to the South Korean market.

Everest Organics is engaged in the manufacturing of active pharmaceutical ingredients and bulk drugs.

The company's standalone net profit surged to Rs 1.14 crore in Q3 FY25 as against Rs 0.02 crore posted in Q3 FY24. However, revenue from operations fell 19.9% YoY to Rs 42.05 crore in the quarter ended 31 December 2024.